ライフサイエンスコーパス: valproate

1 s (carbamazepine, lamotrigine, phenytoin and valproate).

2 psychosis with the use of divalproex sodium (valproate).

3 ne, flunarizine, pizotifen, propranolol, and valproate.

4 r medications such as clobazam and/or sodium valproate.

5 s in common clinical use--lithium and sodium valproate.

6 r older AEDs namely carbamazepine and sodium valproate.

7 ine and histone deacetylase inhibitor sodium valproate.

8 ection against suicidal behavior compared to valproate.

9 ypically responsive to treatment with sodium valproate.

10 ileptic agents phenytoin, phenobarbital, and valproate.

11 .71 (0.51-1.00, p=0.0472) for lithium versus valproate.

12 r mood-stabilizing drugs such as lithium and valproate.

13 o carbamazepine, and 92 for those exposed to valproate.

14 ment of the child exposed in utero to sodium valproate.

15 or phenytoin but not among those exposed to valproate.

16 ntrations of the HDACIs vorinostat or sodium valproate.

17 expressing MLL-PTD(+) AML cells treated with valproate.

18 31%) to fosphenyltoin, and 145 (31%) were to valproate.

19 ts of the mood-stabilizing drugs lithium and valproate.

20 as its water-soluble anionic conjugate base valproate.

21 , ameliorated by antimania drugs lithium and valproate.

22 2005 to 2013 for treatment with lithium and valproate.

23 5 years), to levetiracetam, fosphenytoin, or valproate.

24 associated with fewer MCMs than all doses of valproate.

25 d to therapeutic levels of either lithium or valproate.

26 antage, and partially rescued sensitivity to valproate.

27 od autism among 6152 children not exposed to valproate.

28 evant concentration of the anti-bipolar drug valproate (0.6 mm).

29 83, p=0.0023) for combination therapy versus valproate, 0.82 (0.58-1.17, p=0.27) for combination ther

30 in (five), clavulanate/amoxicillin (15), and valproate (11).

31 cetam (145 patients), fosphenytoin (118), or valproate (121).

32 ith 2148 prescribed lithium, 1670 prescribed valproate, 1477 prescribed olanzapine, and 1376 prescrib

33 Valproate (2-propylpentanoate) is a commonly used mood s

34 nt was started at age 26 years or older (24% valproate, 22% lamotrigine).

35 treatment at age younger than 26 years (44% valproate, 23% lamotrigine; p = 0.002) but was similar i

36 = 0.010) and the post hoc (HA) analyses (36% valproate, 23% lamotrigine; p = 0.007).

37 The highest doses of valproate (300 mg/kg) and lamotrigine (30 mg/kg) also el

38 mood stabilizer (lithium, carbamazepine, or valproate), 37 patients were randomly assigned to 6 mont

39 e lamotrigine (59 [83%] of 71; p=0.0287) and valproate (38 [79%] of 40; p=0.0089) groups.

40 group developed (OD) in the prospective (54% valproate, 38% lamotrigine; p = 0.010) and the post hoc

41 risk [PYAR]) compared with those prescribed valproate (392; 95% CI, 334-460 per 10000 PYAR), olanzap

42 rval, 36 to 54), and 56 patients assigned to valproate (46%; 95% credible interval, 38 to 55).

43 to the inositol-depleting drugs lithium and valproate, a loss of function allele of TPI1 was identif

44 Together, these data demonstrate that valproate activates the ERK pathway and induces ERK path

45 Treatment with lithium and valproate activates the extracellular signal-regulated k

46 Although valproate affects the functions of GSK-3 (glycogen synth

47 Valproate also enhanced the rate of the partial steps in

48 Valproate also promoted neural stem cell proliferation-m

49 Valproate amide 3 is orally bioavailable and releases ge

50 le taking study medication; 42 (27 receiving valproate and 15 receiving placebo) reached 24 months ha

51 A total of 122 participants (59 receiving valproate and 63 receiving placebo) completed 24 months

52 previously reported the effects of lithium, valproate and a new antipsychotic, paliperidone on prote

53 effects of the histone deacetylase inhibitor valproate and all-trans retinoic acid (ATRA) in treatmen

54 ttenuation of phosphorylation by lithium and valproate and also brought GluR1 back to the surface, su

55 of SZ patients treated with a combination of valproate and APS in which the expression of DNMT1 faile

56 nts with psychosis received a combination of valproate and APS treatment but not APS monotherapy.

57 Some mood stabilizers, e.g., sodium valproate and carbamazepine, are human teratogens.

58 n of LY379268 on Gadd45-beta was mimicked by valproate and clozapine but not haloperidol.

59 h lower verbal and non-verbal abilities with valproate and for lower verbal abilities with carbamazep

60 there was no significant difference between valproate and lamotrigine (1.25 [0.94-1.68]).

61 ld have effects similar to or different from valproate and lamotrigine in a model of reward and eleva

62 drugs developed as anticonvulsants (notably, valproate and lamotrigine) have therapeutic effects in b

63 ight on the possible mechanisms of action of valproate and lithium in the treatment of the disease.

64 , both combination therapy with lithium plus valproate and lithium monotherapy are more likely to pre

65 both at basal levels and in the presence of valproate and lithium.

66 Lithium, valproate and paliperidone had a substantial and common

67 daily intraperitoneal injections of lithium, valproate and paliperidone.

68 iazepines like clobazam, in combination with valproate and stiripentol, provides only modest seizure

69 there was no significant difference between valproate and topiramate in either the analysis overall

70 ion of antimanic treatments such as lithium, valproate, and carbamazepine.

71 reatment relies on lithium, off-label use of valproate, and growing use of modern antipsychotics.

72 drug monotherapy (phenytoin, carbamazepine, valproate, and lamotrigine).

73 Lithium, valproate, and olanzapine had unequivocal evidence for e

74 etiapine, risperidone long-acting injection, valproate, and placebo).

75 , including the sleep loss, were reversed by valproate, and re-emerged when treatment was stopped.

76 ns with the epigenetic drugs azacytidine and valproate, and tested tumor and self-reactivities of the

77 The anticancer activity of valproate appears to be driven by histone deacetylase in

78 Both lithium and valproate are well-established treatments for bipolar di

79 ar disorder (carbamazepine, lamotrigine, and valproate) are associated with an elevated risk of suici

80 us effectiveness of lamotrigine, topiramate, valproate, aripiprazole, olanzapine, and omega-3 fatty a

81 Propranolol was compared with valproate as well as behavioral treatment, and 2 studies

82 depressed), and treatment group (placebo or valproate) as covariates.

83 In utero exposure to valproate, as compared with other commonly used antiepil

84 thly, aripiprazole+lamotrigine, aripiprazole+valproate, asenapine, carbamazepine, lamotrigine, lamotr

85 f purified MIP synthase was not inhibited by valproate at this concentration, suggesting that inhibit

86 tional studies showed that either lithium or valproate, at therapeutically relevant levels, inhibited

87 ghly dissimilar mood stabilizers lithium and valproate: BAG-1 [BCL-2 (B-cell CLL/lymphoma 2)-associat

88 Sodium valproate, benzodiazepines and topiramate were reported

89 y (carbamazepine, lamotrigine, phenytoin, or valproate) between October, 1999, and February, 2004, at

90 Finally, valproate, but not lithium, increases expression of phos

91 The mood-stabilizing drug valproate, but not lithium, rescues the manic-like behav

92 for pregnancies exposed to <600 mg daily of valproate, but this was not significant (3.4% vs 5.0%, p

93 thus explored the structural optimization of valproate, butyrate, phenylacetate, and phenylbutyrate b

94 e risk of MCMs after monotherapy exposure to valproate, carbamazepine and lamotrigine.

95 l active treatments, other than aripiprazole+valproate, carbamazepine, lamotrigine, and lamotrigine+v

96 In utero exposure to valproate carries a significantly higher MCM risk than l

97 We found that lithium and valproate, commonly used mood stabilizers for the treatm

98 001 [adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs]), drug dosage (regres

99 trations in subjects taking carbamazepine or valproate compared with those taking other antiepileptic

100 0.80-0.99 mEq/L) or divalproex (target serum valproate concentration, 80-99 mug/mL) for 9 weeks.

101 sponse to the histone deacetylase inhibitor, valproate, consistent with the encoded protein-SMCT1-sho

102 Lorazepam, modafinil, and valproate did not influence P50 suppression in low gater

103 Risperidone, amisulpride, and valproate did not influence PPI.

104 Children exposed to valproate did poorly on measures of verbal and memory ab

105 Performance was negatively associated with valproate dose for both verbal and non-verbal domains an

106 as found to be repressed by steatotic drugs (valproate, doxycycline, tetracycline, and cyclosporin A)

107 rs were used to identify children exposed to valproate during pregnancy and diagnosed with autism spe

108 Maternal use of valproate during pregnancy was associated with a signifi

109 ecause of known potential adverse effects of valproate during pregnancy, the benefits for seizure con

110 ders (quetiapine, olanzapine, and semisodium valproate) during the same period (retrospectively assig

111 lsant drugs levetiracetam, fosphenytoin, and valproate each led to seizure cessation and improved ale

112 Similar to neurotrophic factors, valproate enhanced ERK pathway-dependent cortical neuron

113 Chronic treatment with valproate enhanced neurogenesis in the dentate gyrus of

114 In the presence of GABA, however, valproate enhanced the GABA-evoked steady-state inward c

115 The valproate enhancement did not alter the Na(+) or Cl(-) d

116 ments under voltage clamp suggested that the valproate enhancement of the GABA-evoked current was mat

117 Fetal valproate exposure has dose-dependent associations with

118 We previously reported that foetal valproate exposure impairs intelligence quotient.

119 igine has a favourable profile compared with valproate for adverse pregnancy outcomes, the requiremen

120 response and that the target blood level of valproate for best response in acute mania is above 94 m

121 the treatment benefits for women who require valproate for epilepsy control.

122 agent, as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression.

123 el, only phenytoin proved ineffective, while valproate, gabapentin and carbamazepine varied in their

124 that several antiepileptic agents, including valproate, gabapentin and phenytoin, reduced the ability

125 he lithium group, and 76 (69%) of 110 in the valproate group had a primary outcome event during follo

126 The valproate group had a significantly lower proportion of

127 The valproate group had higher rates of somnolence, gait dis

128 cation adherence was added as covariate, the valproate group had significantly fewer drinks per heavy

129 imaging scans at baseline and 12 months; the valproate group showed greater loss in hippocampal and w

130 More women in the valproate group than the lamotrigine group developed (OD

131 More women in the valproate group than the lamotrigine group developed PCO

132 ix from the lithium group and eight from the valproate group.

133 igher in the placebo group compared with the valproate group.

134 our study overall and in the lamotrigine and valproate groups.

135 Overall, the 508 children exposed to valproate had an absolute risk of 4.42% (95% CI, 2.59%-7

136 On average, children exposed to valproate had an IQ score 9 points lower than the score

137 Lithium reduced impulsivity, whereas valproate had no effect on choice behavior.

138 lind trial of ethosuximide, lamotrigine, and valproate had short-term seizure outcome determined.

139 Sodium valproate has been a first-line antiepileptic drug for 4

140 While valproate has been implicated as having particularly not

141 Prescribing of carbamazepine and sodium valproate have declined since 1994 despite being the mos

142 ing for clustering by primary care practice (valproate hazard ratio [HR] 0.56; 95% confidence interva

143 Valproate, however, has been found to exert an antiproli

144 Rates of new onset hyperthyroidism (valproate HR 0.24; 95% CI 0.09-0.61; p = 0.003, olanzapi

145 CI 0.13-0.73; p = 0.007) and hypercalcemia (valproate HR 0.25; 95% CI 0.10-0.60; p = 0.002, olanzapi

146 ate, olanzapine, and quetiapine were higher (valproate HR 1.62; 95% CI 1.31-2.01; p < 0.001, olanzapi

147 Hypothyroidism was reduced in those taking valproate (HR 0.60; 95% CI 0.40-0.89; p = 0.012) and ola

148 y rates were lower for lithium compared with valproate (HR, 1.32; 95% CI, 1.10-1.58) and quetiapine (

149 tiagabine (HR, 2.41; 95% CI, 1.65-3.52), and valproate (HR, 1.65; 95% CI, 1.25-2.19), compared with t

150 d, placebo-controlled trial of flexible-dose valproate in 313 (of 513 screened) individuals with mode

151 s, and 35% (17-59) of older adults; and with valproate in 52% (41-63) of children, 46% (34-58) of adu

152 d safety of levetiracetam, fosphenytoin, and valproate in established status epilepticus, and here we

153 re are now preliminary reports of the use of valproate in human haematological and solid tumours.

154 g treatment with lamotrigine, topiramate and valproate in patients diagnosed with generalised or uncl

155 e, whereas apoptosis occurred in response to valproate in PELs that supported lytic replication of HH

156 ildhood autism in children after exposure to valproate in pregnancy.

157 rovide evidence that incubation of PELs with valproate in the presence of ganciclovir or PFA can sele

158 We tested lacosamide, lamotrigine, and valproate in the rat ICSS test alone or in the presence

159 l detected no difference between lithium and valproate in time to suicide attempt or suicide event in

160 ars of age, children who had been exposed to valproate in utero had significantly lower IQ scores tha

161 l difficulties in children exposed to sodium valproate in utero.

162 ve agents - levetiracetam, fosphenytoin, and valproate - in children and adults with convulsive statu

163 t (carbamazepine, lamotrigine, phenytoin, or valproate) in a prospective, observational, multicenter

164 ility of the anticonvulsant mood stabilizer, valproate, in bipolar disorder with co-occurring alcohol

165 We found that chronic treatment of rats with valproate increased levels of activated phospho-ERK44/42

166 We propose that valproate increases the turnover rate of GABA transporte

167 Ganciclovir and PFA also prevented most valproate-induced expression of the late lytic viral tra

168 terior cingulate, a region in which we found valproate-induced increases in expression of an ERK path

169 lovir and phosphonoformic acid (PFA) blocked valproate-induced production of infectious virus without

170 Valproate is an important anticonvulsant currently in cl

171 Valproate is better tolerated than topiramate and more e

172 Uptake experiments indicated that valproate is not transported by mouse GAT3 in the absenc

173 registers has not only confirmed that sodium valproate is teratogenic but also that it may be associa

174 neurologists had long suspected--that sodium valproate is the most effective drug in the treatment of

175 Valproate is used for the treatment of epilepsy and othe

176 Valproate is widely accepted as a drug of first choice f

177 Another older AED, valproate, is associated with the occurrence of polycyst

178 not cotreatment, with interferon attenuators valproate, Jak1 inhibitor, or vaccinia virus B18R protei

179 er mood-stabilizing treatments of BD such as valproate, lamotrigine, carbamazepine, oxcarbazepine, an

180 Aripiprazole+valproate, lamotrigine, lamotrigine+valproate, lithium,

181 Patients were randomly assigned to valproate, lamotrigine, or topiramate between Jan 12, 19

182 the presence of the inositol-depleting drug valproate led to an increase in phosphatidylglycerophosp

183 e with that of placebo as well as the lowest valproate level (< =55.0 microg/ml).

184 The mean serum valproate level was then determined for all subjects wit

185 ies have shown that achieving adequate serum valproate levels is critical to rapid stabilization of a

186 71.4-85.0 microg/ml range and for all higher valproate levels; the 94.1-107.0 and >107.0 microg/ml gr

187 pilepticus) modern treatment choices include valproate, levetiracetam and lacosamide.

188 pileptic agents such as topiramate, disodium valproate, levetiracetam, the antihistamine cyproheptadi

189 quetiapine, and ziprasidone) with lithium or valproate (LIT/VAL) compared with placebo with LIT/VAL.

190 ine, carbamazepine, lamotrigine, lamotrigine+valproate, lithium, lithium+oxcarbazepine, lithium+valpr

191 iprazole+valproate, lamotrigine, lamotrigine+valproate, lithium, olanzapine, and quetiapine outperfor

192 ggest that at its therapeutic concentration, valproate may enhance the activity of neuronal and glial

193 Valproate may enhance transcription and reverse SMN2 spl

194 However, prenatal exposure to valproate may increase the risk of autism.

195 ed that age-6 IQ was lower after exposure to valproate (mean 97, 95% CI 94-101) than to carbamazepine

196 plasma concentration 0.4-1.0 mmol/L, n=110), valproate monotherapy (750-1250 mg, n=110), or both agen

197 events after randomisation: seven receiving valproate monotherapy (three deaths); five lithium monot

198 The MCM risk with valproate monotherapy exposure in utero was 6.7% (95% CI

199 1290 women were exposed to valproate monotherapy, 1718 to carbamazepine monotherapy

200 y are more likely to prevent relapse than is valproate monotherapy.

201 ls; and Group V, 7 patients receiving sodium valproate monotherapy.

202 rder and were prescribed lithium (n = 2148), valproate (n = 1670), olanzapine (n = 1477), or quetiapi

203 Participants were randomized to 12 months of valproate (n = 225) or lamotrigine (n = 222) therapy.

204 pride and lorazepam (n=30), or modafinil and valproate (n=30), and placebo.

205 tments other than carbamazepine, lamotrigine+valproate (no data) and paliperidone outperformed the pl

206 For valproate, no effect was observed (17.8% with valproate

207 With valproate, no survival difference was observed.

208 This finding supports a recommendation that valproate not be used as a first-choice drug in women of

209 azid, phenytoin, clavulanate/amoxicillin, or valproate occurring since 1994.

210 served (17.8% with valproate v 17.2% without valproate; odds ratio, 1.06; 95% CI, 0.51 to 2.21; one-s

211 to patients prescribed lithium, those taking valproate, olanzapine, and quetiapine had reduced rates

212 er, rates of greater than 15% weight gain on valproate, olanzapine, and quetiapine were higher (valpr

213 e event rates during treatment with lithium, valproate, olanzapine, and quetiapine.

214 ipolar disorder who were prescribed lithium, valproate, olanzapine, or quetiapine as maintenance mood

215 zard ratio [HR], 1.40; 95% CI, 1.12-1.74 for valproate, olanzapine, or quetiapine vs lithium) and PS

216 ate, lithium, lithium+oxcarbazepine, lithium+valproate, olanzapine, paliperidone, quetiapine, risperi

217 acer uptake methods to examine the effect of valproate on a gamma-aminobutyric acid (GABA) transporte

218 ssessed effects of treatment with lithium or valproate on cognitive impulsivity in selectively bred m

219 nterventions, and were randomized to receive valproate or placebo.

220 with high seizure frequency and in those on valproate or polytherapy.

221 acid's, their related drug-congeners (e.g., valproate) or even diet-derived butyrate (from fermentat

222 ntiepileptic (carbamazepine, lamotrigine, or valproate) or not exposed to an antiepileptic, an antide

223 ds immediacy, and then treated with lithium, valproate, or control chow.

224 napine, lithium, olanzapine, quetiapine, and valproate outperformed placebo for all-cause discontinua

225 carbamazepine, lamotrigine, and lamotrigine+valproate, outperformed placebo for RR-mania.

226 A significant dose effect was seen with valproate (p=0.0006) and carbamazepine (p=0.03) exposed

227 ndomly assigned to treatment with lithium or valproate, plus adjunctive medications as indicated, in

228 Ketogenic diet, diazepam, valproate, potassium bromide and stiripentol attenuate m

229 Topiramate, valproate, propranolol, amitriptyline, and methysergide

230 intained on therapeutic levels of lithium or valproate received a single intravenous infusion of eith

231 intained at therapeutic levels of lithium or valproate received an intravenous infusion of either ket

232 ically relevant concentrations of lithium or valproate reduced hippocampal synaptosomal GluR1 levels.

233 ion of seizures by the common antiepileptic, valproate, reduced the overlap of astrocytic processes.

234 hly dissimilar, antimanic agents lithium and valproate regulate synaptic expression of AMPA receptor

235 -12.66; RR 2.58, 1.33-5.39), or lithium plus valproate (RR 5.95, 1.02-33.33; RR 4.09, 1.01-16.96).

236 ubtedly a phamacogenetic component to sodium valproate's teratogenic and neurodevelopmental effects.

237 Lithium carbonate and valproate semisodium are both recommended as monotherapy

238 that there is a linear relationship between valproate serum concentration and response and that the

239 Higher valproate serum concentration significantly correlated w

240 microg/ml groups were superior to the lowest valproate serum level group.

241 =374) were stratified into seven groups (six valproate serum level ranges and placebo), and effect si

242 ent with lurasidone adjunctive to lithium or valproate significantly improved depressive symptoms and

243 d with fewer migraine headaches per month vs valproate (standardized mean difference [SMD], -0.20; 95

244 In valproate subjects, no common polymorphisms were associa

245 showed that MIPS is indirectly inhibited by valproate, suggesting that the enzyme is post-translatio

246 ects receiving carbamazepine, phenytoin, and valproate than in those receiving lamotrigine (p = 0.008

247 Development of HA was more frequent with OD valproate than lamotrigine among those initiating treatm

248 elopment of HA occurred more frequently with valproate than lamotrigine, especially if medication was

249 Lithium and valproate, the drugs presently used to treat mania assoc

250 Findings regarding the effect of valproate, the most common alternative to lithium, are i

251 Valproate therapy decreases heavy drinking in patients w

252 Valproate time and concentration dependently increased a

253 rs after menarche (177 lamotrigine, (HA) 186 valproate) to exclude OD the confounding effect of puber

254 s attenuated in hippocampus from lithium- or valproate-treated animals in vivo.

255 ence interval [CI] 0.78-0.95) but not during valproate treatment (hazard ratio 1.02, 95% CI 0.89-1.15

256 Participants were randomly assigned to valproate treatment at a target dose of 10 to 12 mg per

257 Valproate treatment did not delay emergence of agitation

258 In addition, lithium or valproate treatment promotes neurogenesis, neurite growt

259 Lithium and valproate, two structurally different anti-bipolar drugs

260 In the absence of GABA, valproate (up to 50 mm) had no noticeable effect on the

261 The association between valproate use and IQ was dose dependent.

262 alproate, no effect was observed (17.8% with valproate v 17.2% without valproate; odds ratio, 1.06; 9

263 The local diffusion constants for valproate/valproic acid along the bilayer normal are fou

264 When valproate (VPA) (2 mmol/kg) or MS-275 (0.015-0.12 mmol/k

265 rs in children exposed to monotherapy sodium valproate (VPA) (6/50, 12.0%; aOR 6.05, 95%CI 1.65 to 24

266 combination of atypical antipsychotics with valproate (VPA) (a histone deacetylase inhibitor that ma

267 tam (LEV) 1.00 (0.16 to 1.84) p=0.02; sodium valproate (VPA) 0.74 (0.10 to 1.38) p=0.02; topiramate (

268 Sodium valproate (VPA) administered to neonatal mice causes cog

269 Valproate (VPA) and lithium, widely used for the treatme

270 The HDACIs sodium butyrate (NaB), valproate (VPA) and suberoylanilide hydroxamic acid (SAH

271 Valproate (VPA) can suppress absence and other seizures,

272 The widely used mood stabilizer valproate (VPA) causes perturbation of energy metabolism

273 reviously shown that the anticonvulsant drug valproate (VPA) depletes inositol by inhibiting myo-inos

274 Valproate (VPA) has been used in the treatment of bipola

275 Valproate (VPA) is a commonly prescribed mood stabilizer

276 Valproate (VPA) is one of the most widely used drugs for

277 Valproate (VPA) is one of the two drugs approved by the

278 Sodium valproate (VPA) is widely used throughout the world to t

279 stration of the antimanic agents lithium and valproate (VPA) reduced synaptic AMPA receptor GluR1/2 i

280 of the histone deacetylase (HDAC) inhibitor valproate (VPA) with atypical antipsychotics has become

281 The mechanism of action of valproate (VPA), a widely prescribed short chain fatty a

282 Administration of valproate (VPA), which can re-instate the critical perio

283 ctrum disorder among 432 children exposed to valproate was 4.15% (95% CI, 2.20%-7.81%) (adjusted HR,

284 Valproate was associated with poorer cognitive outcomes.

285 es) were associated with the lowest risk and valproate was associated with the highest risk (10.93% i

286 e reduction in synaptic GluR1 by lithium and valproate was attributable to a reduction of surface Glu

287 We aimed to establish whether lithium plus valproate was better than monotherapy with either drug a

288 of the study recruited 716 patients for whom valproate was considered to be standard treatment.

289 nts with an idiopathic generalised epilepsy, valproate was significantly better than both lamotrigine

290 For time to 12-month remission valproate was significantly better than lamotrigine over

291 For time to treatment failure, valproate was significantly better than topiramate (haza

292 f suicide-related events between lithium and valproate was statistically significant.

293 High doses of valproate were negatively associated with IQ (r=-0.56, p

294 e, carbamazepine, lamotrigine, phenytoin, or valproate) were enrolled from October 14, 1999, through

295 at the protypical drugs for BPD--lithium and valproate--when administered in therapeutically relevant

296 noninfected BL-41 cells were incubated with valproate, whereas apoptosis occurred in response to val

297 Pharmaceutical agents such as valproate, which counteract the effects of genetically d

298 these mice the histone deacetylase inhibitor valproate, which increases acetylated histone content in

299 irus responded to the antiseizure medication valproate with entry into the lytic cascade and producti

300 imilarly to levetiracetam, fosphenytoin, and valproate, with treatment success in approximately half